Releases Details

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Baird Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, recently sponsored another advanced MWA training session in New Orleans. This program offered physicians practical experience with a state-of-the-art treatment designed to deliver quicker recovery and effective management of thyroid nodules.

Led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, the session welcomed participation from Dr. Sean P. Nikravan, MD, FACE, an endocrinologist based in Newport Beach, CA, and Dr. Erin H. Lin, DO, a specialist in Surgical Oncology and General Surgery from the University of California, Irvine. Both physicians had the opportunity to observe seven live MWA procedures, refine advanced techniques, and evaluate the unique capabilities of this groundbreaking technology. During the hands-on experience, they honed precision targeting of nodules and observed the high efficiency and quick execution of the procedure, emphasizing its streamlined workflow and potential to enhance patient outcomes.

Following the session, Dr. Nikravan and Dr. Lin participated in post-training discussions with Dr. Kandil, exchanging valuable clinical insights and strategies for adopting MWA in diverse clinical settings. Upon completing the program, both physicians were awarded Certificates of Completion, signifying their readiness to incorporate this advanced treatment modality into their practice.

"Advancing the development of MWA for thyroid nodules requires hands-on training and expert collaboration," said Haimei Wu, Chairwoman of Baird Medical. "By supporting specialized programs like this, we are empowering physicians with the practical expertise needed to refine patient care and drive broader adoption of minimally invasive thyroid treatments."

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-sponsored-microwave-ablation-training-advances-thyroid-treatment-302348718.html

SOURCE BDMD

Eric Huang, PR Liaison, Baird Medical LLC, Phone: +1 (888) 508-6228, Email: erichuang@bairdmed.com